15 Years Sounds Ancient in AI. For CRISPR, It's Just the Beginning ✨

New technologies often promise breakthroughs faster than they can deliver. But developing treatments takes time, and CRISPR may finally be entering the phase where years of research start paying off. Dr. Trevor Martin, co-founder and CEO of Mammoth Biosciences, explains why he's optimistic about the next 5 to 10 years of gene editing. With a CRISPR therapy already approved for sickle cell disease and more treatments in development, he believes we could see significant progress in treating genetic diseases. Watch the full episode! #CRISPR #GeneEditing #GeneticMedicine #Biotechnology #MammothBio